ASRS 2023: 'MacGyver-Inspired' endolaser option for chandelier-assisted scleral buckles
July 31st 2023Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.
ASRS 2023: Efficacy/safety of biosimilars ranibizumab-nuna and ranibizumab-eqrn in clinical use
July 30th 2023This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.
ASRS 2023: Annexon to share results of ARCHER Phase 2 trial for the treatment of geographic atrophy
July 28th 2023The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.
BREAKING NEWS: FDA approves XDEMVY for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
EyeCare Partners launches Advanced Comprehensive Ophthalmology Fellowship and opens applications
July 5th 2023The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures and clinical research.